Rivaroxaban

Таблетки By prescription

Oral anticoagulant from the group of direct factor Xa inhibitors

Rivaroxaban

Important

The drug contains the active substance rivaroxaban - a highly selective direct factor Xa inhibitor with high bioavailability when taken orally. It belongs to antithrombotic agents, i.e. drugs that prevent blood clots.

Indications

Rivaroxaban is indicated for use in adults for the prevention of:
- death due to cardiovascular causes, myocardial infarction and stent thrombosis in patients after acute coronary syndrome (ACS) with elevated, cardiac-specific biomarkers, in combination therapy with acetylsalicylic acid (ASC) or with ASC and clopidogrel or ticlopidine;
- stroke, myocardial infarction and death due to cardiovascular causes, as well as prevention of acute limb ischaemia and total mortality in patients with coronary heart disease (CHD) or peripheral arterial disease (PAD) in combination therapy with ASC.

Contraindications

Do not use Rivaroxaban:
- If you are allergic to rivaroxaban or any other components of the drug (listed in section 6 of the leaflet);
- if you have clinically significant active bleeding (e.g. intracranial haemorrhage, gastrointestinal bleeding);
- if you have diseases or conditions associated with an increased risk of major bleeding (e.g. existing or recent gastrointestinal ulcer, malignancy with a high risk of bleeding, recent trauma to the brain or spinal cord, recent brain, spinal cord or eye surgery, recent intracranial haemorrhage, diagnosed or suspected oesophageal varices, arteriovenous malformations (occurrence of m bleeding), or if you are at high risk of bleeding.
- If you are taking any other anticoagulants as concomitant therapy (e.g. heparin, low molecular weight heparins: enoxaparin, dalteparin, fraxiparin, other heparin derivatives - fondaparinux, oral anticoagulants: warfarin, apixaban, dabigatran), unless you are being switched from or to therapy with Rivaroxaban, or if heparin is prescribed in low doses to maintain patency of a central venous or arterial catheter;
- if you have had a stroke or transient ischaemic attack and are being treated for ACS with antiaggregants;
- if you have ischaemic heart disease or peripheral arterial disease with previous brain haemorrhage (stroke) or blockage of small arteries delivering blood to brain tissue (lacunar stroke) or thrombus formation in brain vessels (ischaemic, non-lacunar stroke) within the last month and you are taking ASCs at the same time;
- if you have liver disease with a high risk of bleeding (impaired blood clotting ability);
- if you have severe renal impairment (creatinine clearance < 15 ml/min);
- if you are pregnant or breastfeeding.

Usage

Always use the medicine in full compliance with the leaflet or with the recommendations of your doctor or pharmacist. If in doubt, consult your doctor.
Recommended dose
The recommended dose is 2.5 mg (1 tablet) 2 times a day. Rivaroxaban is not prescribed alone, without other antithrombotic medicines. Your doctor will also prescribe ASC (usually 75 100 mg per day) or combination of ASC with clopidogrel or ticlopidine (after ACS) (75-100 mg per day of ASC and 75 mg per day of clopidogrel or standard daily dose of ticlopidine).

Download full instruction

Report undesirable reaction

If you have information about undesirable reaction after taking the drug

Hotline +7 (495) 984-28-47

Report

Have questions? Contact Us

Has contraindications. Needs specialist overview.

Please read our privacy policy

The present personal data processing policy is drawn up in accordance with the requirements of the Federal Law of July 27, 2006. No. 152-FЗ “On Personal Data” and determines the procedure for processing personal data and measures to ensure the security of personal data of Mir-Pharm LLC (hereinafter referred to as the Operator).

The operator sets as his most important goal and condition for the implementation of his activities the respect for the rights and freedoms of man and citizen in the processing of his personal data, including the protection of the rights to privacy, personal and family confidentiality.

The Operator's policy regarding the processing of personal data (hereinafter - the Policy) applies to all information that the Operator can receive about visitors of the website https://mirpharm.ru.

The user can get any clarification on issues of interest regarding the processing of his personal data by contacting the Operator via e-mail info@mirpharm.ru.

The current version of the Policy is located in free access on the Internet at https://mirpharm.ru/policy.

This document will reflect any changes in the policy of processing personal data by the Operator. The policy is valid indefinitely until it is replaced with a new version.